Acoramidis Shows Sustained Mortality Benefit in ATTR-CM Patients After 42 Months
核心洞察
BridgeBio's acoramidis demonstrates a continued reduction in all-cause mortality and cardiovascular-related hospitalizations in patients with transthyretin amyloid cardiomyopathy (搜索) (ATTR-CM (搜索)).
Data from the open-label extension of the ATTRibute-CM Phase 3 study show consistent benefits over 42 months of treatment with acoramidis.
The findings will be presented at the American Heart Association (AHA) Scientific Sessions in November, highlighting the drug's potential to improve outcomes in ATTR-CM (搜索) patients.
BridgeBio Pharma announced that new data from the open-label extension (OLE) of the ATTRibute-CM Phase 3 study of acoramidis in transthyretin amyloid cardiomyopathy (搜索) (ATTR-CM (搜索)) will be presented at the American Heart Association (AHA) Scientific Sessions in Chicago, Illinois, November 16 – 18, 2024. The presentation will feature outcomes data collected through 42 months, demonstrating the long-term effects of acoramidis on mortality and cardiovascular health.
Acoramidis Reduces Mortality and Hospitalizations
The oral presentation, titled "Acoramidis Reduces All-Cause Mortality (ACM) and Cardiovascular-Related Hospitalization (CVH): Initial Outcomes from the ATTRibute-CM Open-Label Extension (OLE) Study," will be given by Daniel Judge, M.D. of the Medical University of South Carolina on Monday, November 18. The data will highlight the sustained reduction in all-cause mortality and cardiovascular-related hospitalizations observed in patients treated with acoramidis over the extended follow-up period. This suggests a durable benefit of the drug in managing ATTR-CM (搜索).
Additional Insights into ATTR-CM
In addition to the main presentation, BridgeBio will share three moderated digital posters providing further insights into ATTR-CM (搜索). These include:
- Costs and Healthcare Resource Utilization in Transthyretin Amyloid Cardiomyopathy Exceeds That of Generalized Heart Failure: This poster, presented by Justin Grodin, M.D. of UT Southwestern Medical Center, will explore the economic burden of ATTR-CM, demonstrating that it surpasses that of generalized heart failure.
- Evolving Baseline Risk in Patients with Transthyretin Amyloid Cardiomyopathy: A Systematic Literature Review of Clinical Trials: Ahmad Masri, M.D. of Oregon Health & Science University, will present a systematic review of clinical trials, highlighting the evolving understanding of baseline risk factors in ATTR-CM patients.
- Acoramidis Improved Survival in Patients with Transthyretin Cardiac Amyloidosis Regardless of Prior Cardiovascular Hospitalization: Kevin Alexander, M.D. of Stanford University School of Medicine, will present data indicating that acoramidis improves survival in ATTR-CM patients, irrespective of prior cardiovascular hospitalization history.
These presentations and posters will be available on the Presentations page within the Investors section of the BridgeBio website following the sessions.
About Acoramidis and ATTR-CM
Acoramidis is an investigational drug being developed by BridgeBio Pharma for the treatment of ATTR-CM (搜索), a progressive and fatal disease in which misfolded transthyretin (搜索) protein accumulates in the heart, leading to heart failure. The data presented at AHA 2024 will provide further evidence of acoramidis' potential to address this unmet medical need.